X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NOVARTIS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NOVARTIS ASTRAZENECA PHARMA/
NOVARTIS
 
P/E (TTM) x 137.8 300.3 45.9% View Chart
P/BV x 20.9 25.6 81.7% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ASTRAZENECA PHARMA   NOVARTIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
NOVARTIS
Mar-17
ASTRAZENECA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,285855 150.3%   
Low Rs634666 95.3%   
Sales per share (Unadj.) Rs189.6219.0 86.6%  
Earnings per share (Unadj.) Rs-0.219.1 -1.1%  
Cash flow per share (Unadj.) Rs3.820.3 18.9%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs68.6307.0 22.4%  
Shares outstanding (eoy) m25.0029.96 83.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.5 145.8%   
Avg P/E ratio x-4,712.739.8 -11,838.3%  
P/CF ratio (eoy) x249.637.5 666.3%  
Price / Book Value ratio x14.02.5 564.4%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m23,98822,779 105.3%   
No. of employees `0001.60.7 231.3%   
Total wages/salary Rs m1,6051,393 115.2%   
Avg. sales/employee Rs Th3,040.29,736.2 31.2%   
Avg. wages/employee Rs Th1,029.22,066.8 49.8%   
Avg. net profit/employee Rs Th-3.3849.0 -0.4%   
INCOME DATA
Net Sales Rs m4,7406,562 72.2%  
Other income Rs m92702 13.1%   
Total revenues Rs m4,8327,264 66.5%   
Gross profit Rs m-130259 -50.1%  
Depreciation Rs m10136 281.9%   
Interest Rs m07 0.0%   
Profit before tax Rs m-139917 -15.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5345 1.5%   
Profit after tax Rs m-5572 -0.9%  
Gross profit margin %-2.73.9 -69.4%  
Effective tax rate %-3.737.6 -9.7%   
Net profit margin %-0.18.7 -1.2%  
BALANCE SHEET DATA
Current assets Rs m2,7269,731 28.0%   
Current liabilities Rs m2,4351,830 133.0%   
Net working cap to sales %6.1120.4 5.1%  
Current ratio x1.15.3 21.1%  
Inventory Days Days7449 151.5%  
Debtors Days Days4125 162.0%  
Net fixed assets Rs m1,03557 1,810.0%   
Share capital Rs m50141 35.5%   
"Free" reserves Rs m9429,056 10.4%   
Net worth Rs m1,7169,196 18.7%   
Long term debt Rs m00-   
Total assets Rs m4,15611,499 36.1%  
Interest coverage xNM128.4-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 199.8%   
Return on assets %-0.15.0 -2.4%  
Return on equity %-0.36.2 -4.8%  
Return on capital %010.1 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m375129 290.6%   
Fx outflow Rs m4701,734 27.1%   
Net fx Rs m-96-1,605 6.0%   
CASH FLOW
From Operations Rs m-8-380 2.1%  
From Investments Rs m-1464,208 -3.5%  
From Financial Activity Rs m862-3,318 -26.0%  
Net Cashflow Rs m709510 138.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 15.7 1.6 981.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   12,856 41,647 30.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 19, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS